Vernalis Research and Servier, an independent international pharmaceutical company, are pleased to announce the achievement of a milestone in their most recent oncology drug discovery collaboration on an undisclosed target.
This achievement is within the research collaboration established in January 2017 in which Vernalis’ proprietary fragment and structure-based drug discovery platform is combined with the oncology expertise at Servier on a challenging protein target which is implicated in many different cancers. The financial terms of the agreement are not disclosed. Vernalis will continue to receive research fees, milestones and a share in the downstream success of any products coming out of this new collaboration.
“This achievement further validates our fragment-based drug discovery platform and the strength and success of our relationship with Servier. We look forward to working together to develop exciting new cancer treatment opportunities to add to the already disclosed successes in targeting Bcl-2 and Mcl-1”, commented Mike Wood, Managing Director of Vernalis.
“We are extremely pleased with the progress we are making in partnership with Vernalis on this challenging target illustrating strong drug discovery expertise. This milestone represents a step ahead toward addressing important unmet cancer patient needs,” added Olivier Geneste, Director of Oncology Research at Servier.